New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin

Vaccine

Volumn 26, Issue 48, 2008, Pages 6132-6142

  Bargieri, Daniel Y ^a   Rosa, Daniela S ^a   Braga, Catarina J M ^b   Carvalho, Bruna O ^c   Costa, Fabio T M ^c   Espíndola, Noeli Maria ^b   Vaz, Adelaide José ^b   Soares, Irene S ^b   Ferreira, Luis C S ^b   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

CpG ODN; Flagellin; FliC; P. vivax; TLR5; TLR9; Vaccine

Indexed keywords

EPITOPE; FLAGELLIN; FLAGELLIN FLIC; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2C; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN HIS6MSP19; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 5 AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; FEMALE; FLAGELLIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNIZATION SCHEDULE; INJECTIONS, SUBCUTANEOUS; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; PLASMODIUM VIVAX; SALMONELLA TYPHIMURIUM; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 5; VACCINES, SYNTHETIC;

EID: 55049115986     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.070     Document Type: Article

References (69)

1. Price R.N., Tjitra E., Guerra C.A., Yeung S., White N.J., and Anstey N.M. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77 December (6 Suppl.) (2007) 79-87
2. Baird J.K. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48 November (11) (2004) 4075-4083
3. Baird J.K. Neglect of Plasmodium vivax malaria. Trends Parasitol 23 November (11) (2007) 533-539
4. Rogers W.O., Gowda K., and Hoffman S.L. Construction and immunogenicity of DNA vaccine plasmids encoding four Plasmodium vivax candidate vaccine antigens. Vaccine 17 August 6 (3-24) (1999) 3136-3144
5. Castellanos A., Arevalo-Herrera M., Restrepo N., Gulloso L., Corradin G., and Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias do Instituto Oswaldo Cruz 102 June (3) (2007) 411-416
6. Herrera S., Bonelo A., Perlaza B.L., Fernandez O.L., Victoria L., Lenis A.M., et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73 November (5 Suppl.) (2005) 3-9
7. Arevalo-Herrera M., Solarte Y., Yasnot M.F., Castellanos A., Rincon A., Saul A., et al. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am J Trop Med Hyg 73 November (5 Suppl.) (2005) 32-37
8. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., Miura K., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 May 2 (24) (2005) 3131-3138
9. Collins W.E., Barnwell J.W., Sullivan J.S., Nace D., Williams T., Bounngaseng A., et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 74 February (2) (2006) 215-221
10. Ramjanee S., Robertson J.S., Franke-Fayard B., Sinha R., Waters A.P., Janse C.J., et al. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25 January 15 (5) (2007) 886-894
11. Miura K., Keister D.B., Muratova O.V., Sattabongkot J., Long C.A., and Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J 6 (2007) 107
12. Saul A., Hensmann M., Sattabongkot J., Collins W.E., Barnwell J.W., Langermans J.A., et al. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite immunol 29 October (10) (2007) 525-533
13. Herrera S., Corradin G., and Arevalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23 March (3) (2007) 122-128
14. Valderrama-Aguirre A., Quintero G., Gomez A., Castellanos A., Perez Y., Mendez F., et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 73 November (5 Suppl.) (2005) 16-24
15. Dutta S., Ware L.A., Barbosa A., Ockenhouse C.F., and Lanar D.E. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, Merozoite Surface Protein 1, expressed in Escherichia coli. Infect Immun 69 September (9) (2001) 5464-5470
16. Sachdeva S., Ahmad G., Malhotra P., Mukherjee P., and Chauhan V.S. Comparison of immunogenicities of recombinant Plasmodium vivax Merozoite Surface Protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli. Infect Immun 72 October (10) (2004) 5775-5782
17. Dutta S., Kaushal D.C., Ware L.A., Puri S.K., Kaushal N.A., Narula A., et al. Merozoite Surface Protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys. Infect Immun 73 September (9) (2005) 5936-5944
18. Devi Y.S., Mukherjee P., Yazdani S.S., Shakri A.R., Mazumdar S., Pandey S., et al. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 25 July 9 (28) (2007) 5166-5174
19. Kocken C.H., Dubbeld M.A., Van Der Wel A., Pronk J.T., Waters A.P., Langermans J.A., et al. High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infecti Immun 67 January (1) (1999) 43-49
20. Arevalo-Herrera M., Castellanos A., Yazdani S.S., Shakri A.R., Chitnis C.E., Dominik R., et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73 November (5 Suppl.) (2005) 25-31
21. Grimberg B.T., Udomsangpetch R., Xainli J., McHenry A., Panichakul T., Sattabongkot J., et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 4 December (12) (2007) e337
22. Chitnis C.E., and Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol 24 January (1) (2008) 29-34
23. Oliveira-Ferreira J., Vargas-Serrato E., Barnwell J.W., Moreno A., and Galinski M.R. Immunogenicity of Plasmodium vivax Merozoite Surface Protein-9 recombinant proteins expressed in E. coli. Vaccine 22 May 7 (15-16) (2004) 2023-2030
24. Rojas Caraballo J., Delgado G., Rodriguez R., and Patarroyo M.A. The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys. Vaccine 25 May 4 (18) (2007) 3713-3721
25. Blackman M.J., Heidrich H.G., Donachie S., McBride J.S., and Holder A.A. A single fragment of a malaria Merozoite Surface Protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172 July 1 (1) (1990) 379-382
26. O'Donnell R.A., Saul A., Cowman A.F., and Crabb B.S. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. Nat Med 6 January 1 (2000) 91-95
27. Cunha M.G., Rodrigues M.M., and Soares I.S. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors. Vaccine 20 November 12 (3-4) (2001) 385-396
28. Rodrigues M.H., Cunha M.G., Machado R.L., Ferreira Jr. O.C., Rodrigues M.M., and Soares I.S. Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the Merozoite Surface Protein-1. Malar J 2 November 14 (1) (2003) 39
29. Rosa D.S., Tzelepis F., Cunha M.G., Soares I.S., and Rodrigues M.M. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 92 April 15 (3) (2004) 259-268
30. Bargieri D.Y., Rosa D.S., Lasaro M.A., Ferreira L.C., Soares I.S., and Rodrigues M.M. Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax Merozoite Surface Protein-1 delivered via the intranasal route. Memorias do Instituto Oswaldo Cruz 102 June (3) (2007) 313-317
31. Rosa D.S., Iwai L.K., Tzelepis F., Bargieri D.Y., Medeiros M.A., Soares I.S., et al. Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect/Institut Pasteur 8 July (8) (2006) 2130-2137
32. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
33. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 February 24 (4) (2006) 783-801
34. Miao E.A., Alpuche-Aranda C.M., Dors M., Clark A.E., Bader M.W., Miller S.I., et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 7 June (6) (2006) 569-575
35. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4 December (12) (2003) 1247-1253
36. Franchi L., Amer A., Body-Malapel M., Kanneganti T.D., Ozoren N., Jagirdar R., et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 7 June (6) (2006) 576-582
37. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 74 January (1) (2006) 694-702
38. Pino O., Martin M., and Michalek S.M. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect Immun 73 October (10) (2005) 6763-6770
39. Honko A.N., Sriranganathan N., Lees C.J., and Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74 February (2) (2006) 1113-1120
40. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., and Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72 May (5) (2004) 2810-2816
41. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25 January 8 (4) (2007) 763-775
42. McDonald W.F., Huleatt J.W., Foellmer H.G., Hewitt D., Tang J., Desai P., et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 195 June 1 (11) (2007) 1607-1617
43. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26 January 10 (2) (2008) 201-214
44. Applequist S.E., Rollman E., Wareing M.D., Liden M., Rozell B., Hinkula J., et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 175 September 15 (6) (2005) 3882-3891
45. Schmitt C.K., Darnell S.C., and O'Brien A.D. The attenuated phenotype of a Salmonella typhimurium flgM mutant is related to expression of FliC flagellin. J Bacteriol 178 May (10) (1996) 2911-2915
46. Barnwell J.W., Galinski M.R., DeSimone S.G., Perler F., and Ingravallo P. Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp Parasitol 91 March (3) (1999) 238-249
47. Soares I.S., Levitus G., Souza J.M., Del Portillo H.A., and Rodrigues M.M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax Merozoite Surface Protein 1 in individuals exposed to malaria. Infect Immun 65 May (5) (1997) 1606-1614
48. Soares I.S., da Cunha M.G., Silva M.N., Souza J.M., Del Portillo H.A., and Rodrigues M.M. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax Merozoite Surface Protein 1. Am J Trop Med Hyg 60 March (3) (1999) 357-363
49. Soares I.S., Barnwell J.W., Ferreira M.U., Gomes Da Cunha M., Laurino J.P., Castilho B.A., et al. A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. Mol Med 5 July (7) (1999) 459-470
50. Rodrigues M.M., Ribeirao M., Pereira-Chioccola V., Renia L., and Costa F. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun 67 August (8) (1999) 3855-3863
51. Ljungström I, Perlmann H, Schlichtherle M, Scherf A, Wahlgren M. Methods in malaria research. 4th ed. Manassas, Virginia, USA: MR4/ATCC; 2004.
52. Majarian W.R., Daly T.M., Weidanz W.P., and Long C.A. Passive immunization against murine malaria with an IgG3 monoclonal antibody. J Immunol 132 June (6) (1984) 3131-3137
53. Spencer Valero L.M., Ogun S.A., Fleck S.L., Ling I.T., Scott-Finnigan T.J., Blackman M.J., et al. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii Merozoite Surface Protein 1 suppresses parasitemia. Infect Immun 66 August (8) (1998) 3925-3930
54. Daly T.M., and Long C.A. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL Merozoite Surface Protein 1 induces a protective immune response in mice. Infect Immun 61 June (6) (1993) 2462-2467
55. Ling I.T., Ogun S.A., and Holder A.A. Immunization against malaria with a recombinant protein. Parasite Immunol 16 February (2) (1994) 63-67
56. Hirunpetcharat C., Tian J.H., Kaslow D.C., van Rooijen N., Kumar S., Berzofsky J.A., et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the Merozoite Surface Protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4 + T cells. J Immunol 159 October 1 (7) (1997) 3400-3411
57. Rotman H.L., Daly T.M., Clynes R., and Long C.A. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. J Immunol 161 August 15 (4) (1998) 1908-1912
58. Bates M.D., Newbold C.I., Jarra W., and Brown K.N. Protective immunity to malaria: studies with cloned lines of Plasmodium chabaudi chabaudi in CBA/Ca mice. III. Protective and suppressive responses induced by immunization with purified antigens. Parasite Immunol 10 January (1) (1988) 1-15
59. Didierlaurent A., Ferrero I., Otten L.A., Dubois B., Reinhardt M., Carlsen H., et al. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 172 June 1 (11) (2004) 6922-6930
60. Cunningham A.F., Khan M., Ball J., Toellner K.M., Serre K., Mohr E., et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 34 November (11) (2004) 2986-2995
61. Molofsky A.B., Byrne B.G., Whitfield N.N., Madigan C.A., Fuse E.T., Tateda K., et al. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J Exp Med 203 April 17 (40) (2006) 1093-1104
62. Ren T., Zamboni D.S., Roy C.R., Dietrich W.F., and Vance R.E. Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog 2 March (3) (2006) e18
63. Vicente-Suarez I., Takahashi Y., Cheng F., Horna P., Wang H.W., Wang H.G., et al. Identification of a novel negative role of flagellin in regulating IL-10 production. Eur J Immunol 37 November (11) (2007) 3164-3175
64. Perera K.L., Handunnetti S.M., Holm I., Longacre S., and Mendis K. Baculovirus Merozoite Surface Protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun 66 April (4) (1998) 1500-1506
65. Darko C.A., Angov E., Collins W.E., Bergmann-Leitner E.S., Girouard A.S., Hitt S.L., et al. The clinical-grade 42-kilodalton fragment of Merozoite Surface Protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infect Immun 73 January (1) (2005) 287-297
66. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., et al. Immunity to recombinant plasmodium falciparum Merozoite Surface Protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74 August (8) (2006) 4573-4580
67. Malkin E., Long C.A., Stowers A.W., Zou L., Singh S., MacDonald N.J., et al. Phase 1 study of two Merozoite Surface Protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin Trials 2 4 (2007) e12
68. Huaman M.C., Martin L.B., Malkin E., Narum D.L., Miller L.H., Mahanty S., et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum Merozoite Surface Protein-1 in vaccinated volunteers. J Immunol 180 February 1 (3) (2008) 1451-1461
69. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev 4 April (40) (2004) 249-258